EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Datwyler Pharma Packaging
Senior Manager Global Scientific Affairs
Renaud Janssen PhD is the Senior Manager of Global Scientific Affairs at Datwyler Pharma Packaging He frequently presents on international conferences on subjects related to elastomeric and aluminiumplastic closures for pharmaceutical applications Renaud also serves on several standardisation and pharmacopoeia committees as well as on industry task forces
Articles
Automation in Pharmaceutical Sector by Implementation of Artificial Intelligence
Since s AI has been utilised in sectors like banking and financial
Research Insights
Factors Associated with Findings of Published Trials of Drug-Drug Comparisons: Why Some Statins Appear More Efficacious than Others
Kristian Pietras Jessica Pahler Gabriele Bergers Douglas Hanahan Department of Biochemistry and Biophysics Diabetes Center and Comprehensive Cancer Center University of California San Francisco San Francisco California United States of America Ludwig Institute for Cancer Research Karolinska Institutet Sto
Case Studies
Isolation Technology: Case Study
A customer active in the hormone production recently searched an appropriate solution for grinding material and clean packaging after the filtering and drying process The following requirements had to be met To provide a safe barrier between the operator and the active drug substance to provide both operator and product protect
Techno Trends
UIC's Scientists Develop a Novel Device to Screen Advanced Crystalline Materials
Researchers and scientists at the University of Illinois at Chicago and AbbVie Inc developed a novel device to screen and test formation of drug substanceActive Pharmaceutical Ingredient API
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Commissioning the 505(b)(2) Pathways in Hastening the Clinical Translation of Various Drugs via Nanotechnological Approaches
Saurabh Srivastava is Associate Professor in Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad. He carries more than 15 years of profound industrial and research experience working with several Pharmaceutical R&Ds, including IPCA labs, Wockhardt research centre and Dr. Reddy’s Laboratories for development and commercialisation of various NDA and ANDA based products for different regulated markets. He is actively involved in execution of several Industrial and Govt. aided research projects for establishment of novel differentiated (505 b 2) product development. He has 02 Commercial Products, 10 International and National Patents, 01 Edited book, 10 Book chapters along with 25 research publications in Journals of International repute to his credit.
Saurabh Shah is currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Hyderabad. He has published 2 research papers, 4 review articles and 2 book chapters in renowned journals. His research focus lies in hastening the clinical translation of nanomedicine-based products from bench to bedside. He has also been involved in numerous industry research and development projects from laboratory to pilot scale up.
Green Synthesis of Metallic Nanoparticles
Ms. Aishwarya Jain is a distinguished pharmaceutical scientist and academician with over six years of experience in pharmaceutical sciences. Currently serving as an Assistant Professor at Sinhgad College of Pharmacy, Vadgaon (Bk), Pune, she has carved a niche for herself in the domains of nanotechnology, green synthesis, and pharmaceutical innovation.
A recipient of 65+ prestigious national and international awards, including the Bharat Shiksha Gaurav Puraskar and the Women Empowerment Award, Ms. Jain is recognised as one of the leading voices in pharmaceutical education and research. Her scholarly contributions span numerous books, book chapters, and high-impact research articles published in top-tier journals indexed in SCOPUS and Web of Science.
Renowned for her commitment to academic excellence and research integrity, she also plays an active role as an editorial board member and peer reviewer for reputed scientific journals and publishing houses. Her work exemplifies a seamless blend of academic rigor and innovative thinking, particularly in green nanotechnology and sustainable drug development.
Driven by a vision to advance pharmaceutical science for global health impact, Ms. Aishwarya continues to inspire through her interdisciplinary collaborations, cutting-edge research, and passionate teaching.
Magnetic Nanoparticles and their Application Studies on Synthesis Characterisation
Prabhanjan S Giram qualified CSIR-NET AIR-81 in chemical sciences and received his Ph. D from National chemical laboratory, Pune. He Received Eudragit® 2018 Award of 1500 Euros from Evonik health care Germany. He also received newton Bhabha Fellowship from British council, UK and DBT, India. He has expertise in synthesis of biocompatible, biodegradable polymer with rationalised design of nanoformulation, nanofiber, semisolid dosage form such as ointment, creams, and gel.
Shubham R Musale has graduate in pharmacy from Savitribai Phule Pune University. He got fellowship for M.pharm from AICTE. The Thesis titled for M.pharm Design of In-expensive Collector for preparation Electrospun Nanofiber. He has 2 review publication and 1 Book Chapter.
Sushil Y Raut has over 12 years of teaching and research experience. He has more than 25 research and review publications. He filed 3 Indian patents and over 20 national as well as international presentations in his credits. He is recipient of international research mobility fellowship and other prestigious awards.
Pharma Firms Must Come Together, Ensure Access to Antibiotics in Poor Countries to Take on Superbugs
Entrusted with the mandate of augmenting and monetising the company’s intellectual property wealth and driving key tactical initiatives, Saransh Chaudhary joined Venus Remedies in 2016 as Strategic Board Advisor after completing his undergraduate degree in Accounting & Finance from Cass Business School, London. Two years later, he assumed charge as President of the company’s Global Critical Care division and CEO of Venus Medicine Research Centre (VMRC), its R&D wing. In these roles, he translates priorities into actionable strategies.
Beyond The Needle
Dr. Sanjesh Kumar is an Assistant Professor at Chandigarh University Uttar Pradesh with a Ph.D. in Pharmacology. An award-winning academician specialized in neurodegenerative disorders and advanced drug delivery, he has authored over 45 high-impact publications and holds multiple patents, seamlessly bridging the gap between clinical research and classroom education.
Dr. Mansi Singh is an academician and researcher serving as Guest Faculty at Babasaheb Bhimrao Ambedkar University, holding a Ph.D. in Pharmacology. A NET and GPAT qualified expert, she is specialized in neuropharmacology and toxicology. She has over six years of teaching experience and has authored more than 40 publications, copyright and multiple patents.
press releasesRead more...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased
Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL
Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders
EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific
EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company
Enhertu approved in the EU as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer
AstraZeneca and Daiichi Sankyos Enhertu trastuzumab deruxtecan has been approved in the European Union EU as a monotherapy for the adjuvant treatment of adult patients with resected HERpositive breast cancer who have residual invasive disease after neoadjuvant taxanebased and HERtargeted treatment
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
Teva Pharmaceuticals International GmbH a subsidiary of Teva Pharmaceutical Industries Ltd today announced that it has completed the acquisition of assets from BioXcel Therapeutics Inc including worldwide rights to BXCL BXCL is an investigational dexmedetomidine
EventsRead more...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
LATEST NEWSRead more...
Adalvo Acquires Romiplostim Biosimilar from Enzene
Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...
Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation
Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement
Pfizer’s TALZENNA Plus XTANDI Approved for Earlier Treatment of Metastatic Prostate Cancer
Pfizer has received approval from the US Food and Drug Administration FDA to expand the use of TALZENNA talazoparib in combination with XTANDI enzalutamide for men with metastatic prostate cancer that is sensitive to hormone treatment and has specific homologous recombination repair HRR gene mutatio...
Okomera Signs Agreement with Servier for Cancer Research Technology
Okomera has signed a commercial agreement with Servier to support the development of new cancer treatments using its tumour miniaturisation technology More than of oncology drug candidates fail to reach the market making it important to identify promising treatments at an early stage Okomeras platf...